You are here

  • Home
  • Archive
  • Volume 66, Issue Suppl 2
  • AODWE-002 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of gemini 1 completers rolling into the gemini open-label extension study

Article info

Article menu
Download PDFPDF
Inflammatory Bowel Disease
AODWE-002 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of gemini 1 completers rolling into the gemini open-label extension study

Authors

Citation

Kaser A, James A, on behalf of the GEMINI open-label extension study authors
AODWE-002 Long-term effectiveness and safety of vedolizumab in patients with ulcerative colitis: 5-year cumulative exposure of gemini 1 completers rolling into the gemini open-label extension study
Gut 2017;66:A120.

Publication history

  • First published June 17, 2017.
Online issue publication 
February 23, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions